​

Prothena (PRTA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PRTA Stock Forecast

Prothena (PRTA) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $25.75, with a high of $36.00 and a low of $11.00. This represents a 144.31% increase from the last price of $10.54.

$10 $16 $22 $28 $34 $40 High: $36 Avg: $25.75 Low: $11 Last Closed Price: $10.54

PRTA Stock Rating

Prothena stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (70.37%), 6 Hold (22.22%), 2 Sell (7.41%), and 0 Strong Sell (0.00%).

Buy
Total 27 0 2 6 19 Strong Sell Sell Hold Buy Strong Buy

PRTA Price Target Upside V Benchmarks

TypeNameUpside
StockProthena144.31%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts344
Avg Price Target$30.67$25.75$25.75
Last Closing Price$10.54$10.54$10.54
Upside/Downside190.99%144.31%144.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25312-17
Sep, 25312-17
Aug, 25313-18
Jul, 25314-19
Jun, 25314-19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025Yasmeen RahimiPiper Sandler$36.00$11.09224.62%241.56%
Oct 28, 2025UBS$36.00$11.31218.30%241.56%
Oct 07, 2025H.C. Wainwright$20.00$9.86102.84%89.75%
Sep 02, 2025Jason ButlerJMP Securities$11.00$8.2733.01%4.36%
Aug 14, 2024Jay OlsonOppenheimer$62.00$19.77213.61%488.24%
Aug 09, 2024Kennen MacKayRBC Capital$24.00$19.6821.95%127.70%
May 09, 2024Kennen MacKayRBC Capital$28.00$23.0321.58%165.65%
Dec 21, 2022Cantor Fitzgerald$98.00$58.9866.16%829.79%
Sep 29, 2022Oppenheimer$110.00$59.4784.97%943.64%
Sep 28, 2022RBC Capital$52.00$55.39-6.12%393.36%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025Piper SandlerOverweightOverweighthold
Oct 07, 2025H.C. WainwrightBuyBuyhold
Dec 19, 2024RBC CapitalSector PerformSector Performhold
Oct 29, 2024OppenheimerOutperformOutperformhold
Oct 01, 2024RBC CapitalSector PerformSector Performhold
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 30, 2024OppenheimerOutperformOutperformhold
Aug 14, 2024OppenheimerOutperformOutperformhold
Aug 09, 2024RBC CapitalSector PerformSector Performhold
May 29, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$-6 $-4 $-2 $0 $2 $4 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.78$1.51$-2.47$-2.76$-2.27----
Avg Forecast$-2.79$1.31$-3.02$-2.79$-2.21$-4.06$-3.26$-1.80$1.93
High Forecast$-1.88$2.30$-1.44$-2.40$-1.75$-0.39$-1.33$1.52$3.92
Low Forecast$-4.88$0.88$-5.26$-2.97$-2.38$-5.71$-5.62$-4.60$0.19
Surprise %-0.36%15.27%-18.21%-1.08%2.71%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$853.00K$200.58M$53.91M$91.37M$135.16M----
Avg Forecast$649.19K$205.49M$43.01M$86.72M$140.55M$63.93M$148.18M$287.26M$598.12M
High Forecast$1.02M$324.16M$67.52M$88.03M$178.18M$114.78M$148.18M$515.73M$1.07B
Low Forecast$485.84K$153.78M$25.71M$86.09M$129.47M$19.47M$148.18M$87.50M$182.19M
Surprise %31.39%-2.39%25.34%5.36%-3.84%----

Net Income Forecast

$-1B $-700M $-400M $-100M $200M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-111.14M$66.97M$-116.95M$-147.03M$-122.31M----
Avg Forecast$-102.52M$81.38M$16.03M$-147.03M$-109.95M$-223.15M$-191.79M$-110.11M$102.60M
High Forecast$-82.01M$122.00M$55.86M$397.14M$-93.12M$-20.54M$-70.78M$80.89M$208.68M
Low Forecast$-123.02M$40.77M$-23.80M$-691.20M$-126.79M$-303.73M$-299.26M$-244.79M$9.85M
Surprise %8.41%-17.70%-829.50%-11.24%----

PRTA Forecast FAQ

Is Prothena stock a buy?

Prothena stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 6 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Prothena is a favorable investment for most analysts.

What is Prothena's price target?

Prothena's price target, set by 27 Wall Street analysts, averages $25.75 over the next 12 months. The price target range spans from $11 at the low end to $36 at the high end, suggesting a potential 144.31% change from the previous closing price of $10.54.

How does Prothena stock forecast compare to its benchmarks?

Prothena's stock forecast shows a 144.31% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Prothena over the past three months?

  • October 2025: 42.86% Strong Buy, 14.29% Buy, 28.57% Hold, 0% Sell, 14.29% Strong Sell.
  • September 2025: 42.86% Strong Buy, 14.29% Buy, 28.57% Hold, 0% Sell, 14.29% Strong Sell.
  • August 2025: 37.50% Strong Buy, 12.50% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.

What is Prothena’s EPS forecast?

Prothena's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.06, marking a 78.85% increase from the reported $-2.27 in 2024. Estimates for the following years are $-3.26 in 2026, $-1.8 in 2027, and $1.93 in 2028.

What is Prothena’s revenue forecast?

Prothena's average annual revenue forecast for its fiscal year ending in December 2025 is $63.93M, reflecting a -52.70% decrease from the reported $135.16M in 2024. The forecast for 2026 is $148.18M, followed by $287.26M for 2027, and $598.12M for 2028.

What is Prothena’s net income forecast?

Prothena's net income forecast for the fiscal year ending in December 2025 stands at $-223M, representing an 82.44% increase from the reported $-122M in 2024. Projections indicate $-192M in 2026, $-110M in 2027, and $102.6M in 2028.